Actemra

(Tocilizumab)

ApprovedMonoclonal antibody

Tocilizumab is used to treat rheumatoid arthritis and other inflammatory conditions by reducing inflammation in the body. It is also used to treat severe COVID-19 in hospitalized patients.[2] Actemra is currently approved and in use across 117 indications[4].[1]

Actemra is one of 1928 small molecule programs targeting Relapsing Polychondritis. It is currently in Approved.

117

Indications

438

Total Trials

Active Trials

1,927

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Relapsing PolychondritisActive, not recruiting

HIV InfectionActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Polymyalgia RheumaticaActive, not recruiting

Erdheim-Chester DiseaseActive, not recruiting

Chronic PancreatitisActive, not recruiting

PanuveitisActive, not recruiting

Non-Hodgkins LymphomaActive, not recruiting

Cardiac ArrestActive, not recruiting

Relapsing PolychondritisPhase 2

Active, not recruiting

HIV InfectionPhase 1

Active, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Cardiovascular DiseaseApproved

Active, not recruiting

Polymyalgia RheumaticaPhase 3

Active, not recruiting

Erdheim-Chester DiseasePhase 2

Active, not recruiting

Chronic PancreatitisPhase 2

Active, not recruiting

PanuveitisPhase 1

Active, not recruiting

Non-Hodgkins LymphomaPhase 3

Active, not recruiting

Cardiac ArrestPhase 2

Active, not recruiting

Showing 10 of 116 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Actemra

Roche

Approved

4 2

Trodelvy

Gilead

Preclinical

37 3

Tecentriq

Roche

Preclinical

36 4

Halaven

Eisai

Preclinical

38 5

Gemzar

GGynecologic Oncology Group

Preclinical

22 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

MS Contin

Merck & Co.

Preclinical

2 8

Voltaren

Novartis

Preclinical

1 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Glioblastoma

NCT04729959

Q4 2026

Post-ApprovalRecruiting

Study completion

NCT06251076

N/ARecruiting

Tocilizumab

NCT07377058

Phase 2Recruiting

Breast Cancer

NCT05846789

Phase 2Active, not recruiting

Immune-Related Adverse Events

NCT04375228

Phase 3Recruiting

Juvenile Idiopathic Arthritis

NCT06654882

Clinical

Trials by Indication[1]

Rheumatoid Arthritis36 trials

To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

Completed·JJW Pharmaceutical·Phase 3·NCT01256736·89 enrolled

Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche··NCT02234960·102 enrolled

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00531817·619 enrolled

Show 33 more trials

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01194414·1,262 enrolled

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer··NCT06418529·21,340 enrolled

Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients

Completed·CChugai Pharma Taiwan·Phase 3·NCT01258712·86 enrolled

Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients

Completed·CChugai Pharma Taiwan·Phase 3·NCT01347983·72 enrolled

Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche··NCT02402686·353 enrolled

A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab

Unknown status·SSungkyunkwan University··NCT04115423·9,508 enrolled

A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs

Completed· Roche logo

Roche·Phase 3·NCT00996606·58 enrolled

A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche·Phase 3·NCT01668966·23 enrolled

A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01462162·122 enrolled

An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy

Completed· Roche logo

Roche·Phase 3·NCT03155347·340 enrolled

A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)

Completed· Roche logo

Roche··NCT02534311·60 enrolled

A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).

Completed· Roche logo

Roche·Phase 3·NCT01734993·11 enrolled

Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01579006·184 enrolled

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01007435·1,162 enrolled

A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche··NCT02797769·48,950 enrolled

Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT02721004·592 enrolled

Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

Completed·JJW Pharmaceutical·Phase 3·NCT01211834·90 enrolled

A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis

Terminated· Roche logo

Roche·Phase 3·NCT01665430·38 enrolled

A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants

Completed· Roche logo

Roche·Phase 3·NCT01941940·227 enrolled

A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)

Completed· Roche logo

Roche··NCT01617005·50 enrolled

A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Completed· Roche logo

Roche·Phase 3·NCT02046616·133 enrolled

Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment

Completed· Roche logo

Roche··NCT03112213·135 enrolled

EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT02648035·200 enrolled

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage

Terminated· Roche logo

Roche·Phase 4·NCT01661140·427 enrolled

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Completed· Roche logo

Roche·Phase 2·NCT01468077·47 enrolled

Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis

Completed· Sanofi logo

Sanofi·Phase 1·NCT02404558·30 enrolled

A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01941095·100 enrolled

An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01664598·49 enrolled

A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.

Completed· Roche logo

Roche·Phase 3·NCT00754559·286 enrolled

Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Completed· Roche logo

Roche··NCT01362062·110 enrolled

A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00721123·538 enrolled

Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis

Terminated·MMassachusetts General Hospital·Phase 4·NCT02659150·16 enrolled

An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01741688·16 enrolled

COVID-1925 trials

Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression

Unknown status·UUniversity of Malaya·Phase 3·NCT04345445·310 enrolled

Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

Terminated·UUniversity of Chicago·Phase 2·NCT04479358·85 enrolled

Tocilizumab Treatment in Patients With COVID-19

Active, not recruiting·IInstituto Nacional de Cancerologia de Mexico·Phase 2·NCT04363853·200 enrolled

Show 22 more trials

Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19

Terminated·HHospital Sao Domingos·Phase 2·NCT04377503·30 enrolled

Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan

Completed·UUNICEF·N/A·NCT04492501·600 enrolled

Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS

Terminated·QQueen's Medical Center·Phase 3·NCT04412772·20 enrolled

Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers

Terminated·BBeneficência Portuguesa de São Paulo·Phase 3·NCT04403685·129 enrolled

Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)

Terminated·HHospital Universitario Ramon y Cajal·Phase 2·NCT04435717·26 enrolled

Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome

Completed·—··NCT04734678·153 enrolled

Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)

Unknown status·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 2·NCT04332094·276 enrolled

Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.

Unknown status·OOctober 6 University·Phase 4·NCT04779047·150 enrolled

Efficacy of Early Administration of Tocilizumab in COVID-19 Patients

Terminated·AAzienda USL Reggio Emilia - IRCCS·Phase 2·NCT04346355·126 enrolled

Randomised Evaluation of COVID-19 Therapy

Recruiting·UUniversity of Oxford·Phase 3·NCT04381936·70,000 enrolled

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Withdrawn·EEmory University·Phase 3·NCT04361552

A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study

Unknown status·KKarolinska University Hospital·Phase 2·NCT04412291·120 enrolled

Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

Unknown status·—·N/A·NCT05279391·150 enrolled

The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation

Unknown status·HHadassah Medical Organization·Phase 4·NCT04377750·500 enrolled

LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients

Unknown status·LLebanese University·Phase 1·NCT05925140·1,000 enrolled

Treatment of COVID-19 Patients With Anti-interleukin Drugs

Completed·UUniversity Hospital, Ghent·Phase 3·NCT04330638·342 enrolled

Tocilizumab for Patients With Cancer and COVID-19 Disease

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT04370834·1 enrolled

A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

Completed· Roche logo

Roche·Phase 1·NCT05164133·2 enrolled

Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial

Completed·—·Phase 3·NCT04678739·205 enrolled

Efficacy of Tocilizumab on Patients With COVID-19

Completed·MMassachusetts General Hospital·Phase 3·NCT04356937·243 enrolled

Tocilizumab Versus Baricitinib in Patients With Severe COVID-19

Completed·UUniversity Hospital of Patras·N/A·NCT05082714·251 enrolled

Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04476979·453 enrolled

Tocilizumab21 trials

Tocilizumab in Chronic Inflammatory CPPD Disease

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT07254637·80 enrolled

A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease

Unknown status·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT04424056·216 enrolled

TOward the Lowest Effective DOse of Abatacept or Tocilizumab

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT01557374·232 enrolled

Show 18 more trials

PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)

Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT06430736·100 enrolled

Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA

Unknown status·—·Phase 2·NCT04239196·58 enrolled

Tocilizumab in Active Moderate-severe Graves' Orbitopathy

Unknown status·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 2·NCT04876534·64 enrolled

Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis

Completed·PPeking Union Medical College Hospital··NCT05133895·12 enrolled

Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

Unknown status·LLille Catholic University·Phase 4·NCT03227419·224 enrolled

RCT of Tocilizumab for Anti-MDA5+DM

Recruiting·PPeking Union Medical College Hospital·N/A·NCT07377058·110 enrolled

Tocilizumab Real-Life Human Factors (RLHFs) Validation Study

Completed· Roche logo

Roche·Phase 4·NCT02682823·91 enrolled

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Completed· Roche logo

Roche·Phase 3·NCT00720798·2,067 enrolled

A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01418989·239 enrolled

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

Not yet recruiting·YYale University·Phase 3·NCT07281027·438 enrolled

Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers

Completed·SSyneos Health·Phase 1·NCT04885829·300 enrolled

Use of Tocilizumab Drug Levels to Optimize Treatment in RA

Recruiting·—·Phase 4·NCT03895879·98 enrolled

Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

Completed· Roche logo

Roche··NCT02608112·291 enrolled

Tocilizumab in Coronavirus-19 Positive Patients

Unknown status·UUniversity of Calgary·Phase 3·NCT04423042·30 enrolled

CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04331808·228 enrolled

A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD

Completed·FFu-Dong Shi·Phase 1/2·NCT03062579·10 enrolled

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

Terminated·—·Phase 4·NCT02353780·10 enrolled

Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab

No longer available·UUniversity of Oklahoma··NCT00862758

Pneumonia6 trials

Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia

Completed·SShaheed Zulfiqar Ali Bhutto Medical University··NCT04873141·24 enrolled

Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab

Unknown status·UUniversity Hospital for Infectious Diseases, Croatia··NCT04359667·30 enrolled

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting·UUMC Utrecht·Phase 3·NCT02735707·20,000 enrolled

Show 3 more trials

A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia

Completed· Roche logo

Roche·Phase 3·NCT04372186·377 enrolled

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

Completed· Roche logo

Roche·Phase 3·NCT04409262·649 enrolled

Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study

Completed·KKaradeniz Technical University··NCT04893031·213 enrolled

Lymphoma5 trials

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Recruiting· Roche logo

Roche·Phase 1/2·NCT03075696·940 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 1/2·NCT03671018·422 enrolled

Show 2 more trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Terminated· Roche logo

Roche·Phase 1·NCT05219513·53 enrolled

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT05364424·43 enrolled

77 more indications

Giant Cell Arteritis5 trials

MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial

Active, not recruiting·—·Phase 3·NCT03892785·230 enrolled

Tocilizumab for Patients With Giant Cell Arteritis

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT01450137·30 enrolled

Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.

Unknown status·—·Phase 4·NCT03244709·15 enrolled

Show 2 more trials

TocilizuMab discontinuAtion in GIant Cell Arteritis

Active, not recruiting·—·Phase 3·NCT06037460·120 enrolled

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

Completed· Roche logo

Roche·Phase 3·NCT01791153·251 enrolled

Multiple Myeloma3 trials

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Active, not recruiting·EEmory University·Phase 1·NCT05391750·7 enrolled

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruiting· Roche logo

Roche·Phase 1/2·NCT05535244·90 enrolled

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Completed· Roche logo

Roche·Phase 1·NCT03275103·355 enrolled

Locally Advanced3 trials

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT03539484·26 enrolled

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02324257·149 enrolled

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Withdrawn· Roche logo

Roche·Phase 1·NCT06372574

Interleukin3 trials

Neutralizing Interleukin (IL)-6

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT07493317·60 enrolled

Role of Interleukin-6 in Exercise

Completed·UUniversity of Zurich·N/A·NCT01073826·56 enrolled

Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

Completed·—·N/A·NCT04690920·200 enrolled

Juvenile Idiopathic Arthritis3 trials

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

Completed· Roche logo

Roche·Phase 1·NCT01904279·52 enrolled

Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis

Terminated·—·Phase 1/2·NCT01603355·3 enrolled

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

Recruiting·—·Phase 3·NCT06654882·400 enrolled

Polymyalgia Rheumatica3 trials

A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)

Completed·MMedical University of Vienna·Phase 3·NCT03263715·39 enrolled

Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Completed·UUniversity Hospital, Brest·Phase 3·NCT02908217·113 enrolled

Study of Tocilizumab to Treat Polymyalgia Rheumatica

Completed·HHospital for Special Surgery, New York·Phase 2·NCT01396317·10 enrolled

Efficacy and Safety3 trials

Efficacy and Safety of Tocilizumab in Adult's Still Disease

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 2·NCT01002781·10 enrolled

Efficacy and Safety of Tocilizumab for TAO

Withdrawn·SSun Yat-sen University·Phase 2·NCT06087731

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT06498089·124 enrolled

Relapsing Polychondritis3 trials

An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

Recruiting·UUniversity of Pennsylvania·Phase 2·NCT06941376·20 enrolled

Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab

Completed·—·N/A·NCT01041248·1 enrolled

Tocilizumab for Relapsing Polychondritis

Withdrawn·MMcMaster Children's Hospital·Phase 2·NCT01104480

Breast Cancer3 trials

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Recruiting·KKathy Miller·Phase 2·NCT05846789·168 enrolled

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Recruiting· Roche logo

Roche·Phase 1/2·NCT03424005·792 enrolled

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT03135171·11 enrolled

Kidney Transplant3 trials

Cell Therapy for Immunomodulation in Kidney Transplantation

Active, not recruiting·TThomas Wekerle·Phase 1/2·NCT03867617·12 enrolled

TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

Recruiting·VVastra Gotaland Region·Phase 3·NCT04561986·50 enrolled

A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation

Completed·—·Phase 1/2·NCT01594424·10 enrolled

Systemic Juvenile Idiopathic Arthritis3 trials

A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)

Completed· Roche logo

Roche·Phase 4·NCT03301883·62 enrolled

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

Completed· Roche logo

Roche·Phase 1·NCT01904292·52 enrolled

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Recruiting· AbbVie logo

AbbVie·Phase 3·NCT05609630·90 enrolled

Non-Small Cell Lung Cancer2 trials

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04940299·35 enrolled

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Recruiting·—·Phase 1/2·NCT04691817·28 enrolled

Ovarian Cancer2 trials

Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer

Completed·LLeiden University Medical Center·Phase 1/2·NCT01637532·21 enrolled

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Recruiting· Regeneron logo

Regeneron·Phase 1/2·NCT03564340·890 enrolled

Chronic Lymphocytic Leukemia2 trials

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Terminated· Roche logo

Roche·Phase 1·NCT02336048·38 enrolled

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT04007029·24 enrolled

Pancreatic Cancer2 trials

Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer

Terminated·HHerlev Hospital·Phase 2·NCT04258150·26 enrolled

Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients

Completed·HHerlev Hospital·Phase 2·NCT02767557·147 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT03677154·188 enrolled

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT04313608·23 enrolled

Respiratory Failure1 trial

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04377659·9 enrolled

Acute Chest Syndrome1 trial

Tocilizumab for Acute Chest Syndrome

Recruiting·UUniversity of Chicago·Phase 2·NCT05640271·200 enrolled

Thrombocytopenia1 trial

Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)

Unknown status·QQin Ning·Phase 4·NCT05604859·350 enrolled

Sts1 trial

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT04066114·24 enrolled

Castleman disease1 trial

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01441063·8 enrolled

Acute Myeloid Leukemia1 trial

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·WWashington University School of Medicine·Phase 1·NCT02057770·25 enrolled

Hepatocellular Carcinoma1 trial

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Completed· Roche logo

Roche·Phase 1·NCT04338685·55 enrolled

Musculoskeletal Ultrasound1 trial

Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab

Completed·UUniversity of California, Los Angeles·Phase 4·NCT01717859·74 enrolled

Esophageal Adenocarcinoma1 trial

Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy

Active, not recruiting·—·Phase 2·NCT04554771·41 enrolled

Single Dose1 trial

Clinical Study of Single Dose IL-6R mAb Injection in RA Patients

Completed·BBeijing VDJBio Co., LTD.·Phase 1·NCT05232396·40 enrolled

Cardiac Arrest1 trial

IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest

Completed·CChristian Hassager·Phase 2·NCT03863015·80 enrolled

Recovery1 trial

IL-6 Regulation of Energy Stores During Recovery From an Acute Exercise Bout

Completed·HHelga Ellingsgaard·N/A·NCT05349149·30 enrolled

Anticoagulation1 trial

Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

Active, not recruiting·—·N/A·NCT06442709·100 enrolled

Hemorrhage1 trial

Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

Recruiting·UUniversity of Florida·Phase 1·NCT06863480·30 enrolled

Familial Mediterranean Fever1 trial

Tocilizumab for the Treatment of Familial Mediterranean Fever

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT03446209·30 enrolled

Status Epilepticus1 trial

Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.

Unknown status·—·Phase 3·NCT05346666·50 enrolled

Takayasu arteritis1 trial

Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02101333·18 enrolled

Chronic Pancreatitis1 trial

Tocilizumab for Painful Chronic Pancreatitis

Recruiting·SSoren Schou Olesen·Phase 2·NCT06426160·36 enrolled

Atherosclerosis1 trial

Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis

Not yet recruiting·ZZhujiang Hospital·Phase 3·NCT06447701·486 enrolled

Systemic Sclerosis1 trial

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Not yet recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT07335562·92 enrolled

Methotrexate1 trial

Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate

Completed·PPatrick Durez·N/A·NCT01245452·30 enrolled

Treatment1 trial

Treatment Tapering in JIA With Inactive Disease

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02840175·62 enrolled

Necrosis1 trial

Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers

Completed·UUniversity of Erlangen-Nürnberg Medical School··NCT02778789·66 enrolled

Fibrosis1 trial

A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT04762784·40 enrolled

Dexamethasone1 trial

Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia

Recruiting·RRadboud University Medical Center·Phase 4·NCT06624436·52 enrolled

Glioblastoma1 trial

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04729959·59 enrolled

Immune-related Adverse Events1 trial

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Active, not recruiting·—·Phase 2·NCT04375228·8 enrolled

Lung Transplantation1 trial

Tocilizumab in Lung Transplantation

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06033196·350 enrolled

Inflammation1 trial

Tocilizumab for Renal Graft Inflammation

Completed·FFlavio Vincenti·Phase 2·NCT02108600·33 enrolled

Solid Tumors1 trial

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT05129280·23 enrolled

Erdheim-Chester disease1 trial

Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease

Terminated·OOspedale San Raffaele·Phase 2·NCT01727206·3 enrolled

Leukemia1 trial

Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)

Completed·NNantes University Hospital·Phase 1·NCT04547062·12 enrolled

Baricitinib1 trial

Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients

Unknown status·—·Phase 3·NCT04693026·150 enrolled

Acute Graft Versus Host Disease1 trial

Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

Terminated·MMedical College of Wisconsin·Phase 1/2·NCT01475162·14 enrolled

Myocardial Infarction1 trial

Short-Term Application of Tocilizumab Following Myocardial Infarction

Completed·KKeesler Air Force Base Medical Center·N/A·NCT02419937·28 enrolled

Ankylosing Spondylitis1 trial

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

Terminated· Roche logo

Roche·Phase 3·NCT01209689·113 enrolled

Major Depressive Disorder1 trial

Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder

Suspended·MMassachusetts General Hospital·Phase 2·NCT03787290·35 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Active, not recruiting·TTianjin Medical University General Hospital·Phase 2/3·NCT06452537·102 enrolled

Mantle Cell Lymphoma1 trial

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

Recruiting·AAustralasian Leukaemia and Lymphoma Group·Phase 2·NCT05833763·42 enrolled

Major Depression1 trial

Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)

Not yet recruiting·HHospital de Clinicas de Porto Alegre·Phase 2·NCT07052058·32 enrolled

Squamous Cell Carcinoma1 trial

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Recruiting·AAlain Algazi·Phase 2·NCT03708224·55 enrolled

Chronic Graft Versus Host Disease1 trial

Tocilizumab for Chronic Graft-versus-Host Disease Treatment

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT02174263

Prostate Cancer1 trial

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Recruiting·DDavid Oh·Phase 2·NCT03821246·68 enrolled

Acute Myocardial Infarction1 trial

Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock

Active, not recruiting·RRigshospitalet, Denmark·Phase 2·NCT05350592·100 enrolled

HIV infection1 trial

AIDS 347: IL-6 Blockade in Treated HIV Infection

Completed·—·Phase 1/2·NCT02049437·34 enrolled

Glucocorticoids1 trial

A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice

Completed· Roche logo

Roche··NCT03291457·101 enrolled

B-cell Malignancies1 trial

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

Active, not recruiting· Roche logo

Roche·Phase 2·NCT05207670·320 enrolled

Autoimmune Disease1 trial

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT07115745·125 enrolled

Cardiovascular Disease1 trial

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Completed· Roche logo

Roche·Phase 4·NCT01331837·3,080 enrolled

Graft Versus Host Disease1 trial

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03434730·46 enrolled

Arthritis1 trial

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

Completed· Roche logo

Roche·Phase 4·NCT01734382·35 enrolled

Urothelial Carcinoma1 trial

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Completed· Roche logo

Roche·Phase 1/2·NCT03869190·272 enrolled

Cytokine Release Syndrome1 trial

Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome

Completed·UUniversity of Pennsylvania·Phase 1·NCT02906371·80 enrolled

Vasculitis1 trial

Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis

Terminated·—·Phase 2·NCT05168475·22 enrolled

Drug Repurposing1 trial

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept

Completed·—··NCT04529863·30,432 enrolled

Hematological Malignancy1 trial

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Terminated·MMedical College of Wisconsin·Phase 1·NCT03588936·2 enrolled

Hematopoietic Stem Cell Transplant1 trial

A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant

Completed·—·Phase 2·NCT02206035·45 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03193190·341 enrolled

Cardiac Transplant1 trial

Tocilizumab in Cardiac Transplantation

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03644667·385 enrolled

Melanoma1 trial

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Completed· Roche logo

Roche·Phase 1·NCT04551352·20 enrolled

Unspecified2 trials

Plan Development for Giving Teclistamab in the Outpatient Setting

Recruiting·UUniversity Health Network, Toronto·Phase 4·NCT06251076·15 enrolled

Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers

Completed·MMycenax Biotech Inc.·Phase 1·NCT03522012·190 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 8, 2010

ACTEMRA

BLA BLA125276

Oct 21, 2013

ACTEMRA

BLA BLA125472

Sep 29, 2023

TOFIDENCE

BLA BLA761354

Jan 24, 2025

AVTOZMA

BLA BLA761420

Jan 21, 2026

AVTOZMA

BLA BLA761498

Sources

References

[1]
ClinicalTrials.gov — 438 trial records for Tocilizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Actemra drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Tocilizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Tocilizumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761498). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Interleukin-6 Receptor Alpha Subunit Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche